首页> 外国专利> IgG Fc A stable liquid formulation of fusion protein with IgG Fc domain

IgG Fc A stable liquid formulation of fusion protein with IgG Fc domain

机译:IgG Fc具有IgG Fc结构域的融合蛋白的稳定液体制剂

摘要

The present invention relates to a fusion protein having the Fc domain of human immunoglobulin G (IgG), particularly the soluble extracellular domain of the vascular endothelial growth factor (VEGF) receptor and the Fc domain of human immunoglobulin G (IgG) And a fusion protein thereof (e.g., an influenzacept)]. The present invention also relates to a composition for stabilizing a protein in which a soluble extracellular domain of a VEGF receptor is fused with an Fc domain of an IgG, and a method for stabilizing a protein in which a soluble extracellular domain of a VEGF receptor is fused with an Fc domain of an IgG. The present invention provides a stable liquid formulation suitable for intraocular injection of an anti-VEGF-Fc fusion protein including Aflibercept to stabilize the physiological activity and to prevent various ocular diseases caused by abnormal angiogenesis (for example, retinal vein occlusion , Diabetic macular edema, choroidal neovascularization, habitual age-related macular degeneration, etc.).
机译:本发明涉及具有人免疫球蛋白G(IgG)的Fc结构域,特别是血管内皮生长因子(VEGF)受体的可溶性细胞外结构域和人免疫球蛋白G(IgG)的Fc结构域的融合蛋白和融合蛋白其(例如流感病毒受体)]。本发明还涉及用于稳定其中其中VEGF受体的可溶性细胞外结构域与IgG的Fc结构域融合的蛋白质的组合物,以及用于稳定其中其中VEGF受体的可溶性细胞外结构域为蛋白质的蛋白的方法。与IgG的Fc结构域融合。本发明提供了一种稳定的液体制剂,该制剂适合于眼内注射包含Aflibercept的抗VEGF-Fc融合蛋白,以稳定生理活性并预防由异常血管生成引起的各种眼部疾病(例如,视网膜静脉阻塞,糖尿病性黄斑水肿,脉络膜新生血管,习惯性年龄相关性黄斑变性等)。

著录项

  • 公开/公告号KR101808234B1

    专利类型

  • 公开/公告日2017-12-12

    原文格式PDF

  • 申请/专利权人 (주)알테오젠;

    申请/专利号KR20160078234

  • 申请日2016-06-22

  • 分类号A61K9;A61K38/17;A61K39/395;A61K47/18;A61K47/26;

  • 国家 KR

  • 入库时间 2022-08-21 12:41:28

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号